1,151
Views
1
CrossRef citations to date
0
Altmetric
Commentary

Against vaccine assay secrecy

, , &
Pages 498-503 | Received 22 Aug 2014, Accepted 04 Sep 2014, Published online: 31 Mar 2015

References

  • Asamoah AK, Sharfstein JM. Transparency at the food and drug administration. N Engl J Med 2010; 362(25):2341-3; PMID:20484392
  • Drazen JM. Transparency for clinical trials–the tEST act. N Engl J Med 2012; 367(9):863-4; PMID:22873430
  • The Lancet. European medicines agency–more transparency needed. Lancet 2010; 375(9728):1753; PMID:20494710
  • Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med 2007; 356(24):2522-4; PMID:17517854
  • United States. Food and drug administration amendments act of 2007, Pub. L. No. 110-85, § 801, 121 Stat. 823, 904-22 (2007)
  • European Commission, Communication from the commission regarding the guideline on the data fields contained in the clinical trials database provided for in article 11 of directive 2001/20/EC to be included in the database on medicinal products provided for in article 57 of regulation (EC) No 726/2004, 2008 OFFICIAL J. EUR. UNION C 168/3, C 168/3 (2008), available at: (last visited: 22, 2013).
  • Viergever RF, Ghersi D. The quality of registration of clinical trials. PLoS ONE 2011; 6(2):e14701; PMID:21383991
  • Prayle AP, Hurley MN, Smyth AR. Compliance with mandatory reporting of clinical trial results on clinical trials.gov: cross sectional study. BMJ 2012; 344(jan03 1):d7373-d7373; PMID:22214756
  • Mathieu S BI. Comparison of registered and published primary outcomes in randomized controlled trials. JAMA 2009; 302(9):977-84; PMID:19724045
  • Sekeres M, Gold JL, Chan A-W, Lexchin J, Moher D, Van Laethem MLP, Maskalyk J, Ferris L, Taback N, Rochon PA. Poor reporting of scientific leadership information in clinical trial registers. PLoS ONE 2008; 3(2):e1610; PMID:18286168
  • Law MR, Kawasumi Y, Morgan SG. Despite law, fewer than one in eight completed studies of drugs and biologics are reported on time on clinical trials.gov. Health Aff 2011; 30(12):2338-2345; PMID:22147862
  • Wieseler B, Wolfram N, McGauran N, Kerekes MF, Vervölgyi V, Kohlepp P, Kamphuis M, Grouven U. Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available ata. PLoS Med 2013; 10(10):e1001526; PMID:24115912
  • Gopal RK, Yamashita TE, Prochazka AV. Research without results: inadequate public reporting of clinical trial results. Contemp Clin Trials 2012; 33(3):486-91; PMID:22342449
  • Doshi P, Jefferson T, Del Mar C. The Imperative to share clinical study reports: recommendations from the tamiflu experience. PLoS Med 2012; 9(4):e1001201; PMID:22505850
  • Herder M. Government regulators must steward drug transparency. Nature Med 2014; 20(8):806; PMID:25100518
  • Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010; 17(7):1055-65; PMID:20463105; http://dx.doi.org/10.1128/CVI.00131-10
  • Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis 2012; 54(11):1615-7; PMID:22437237; http://dx.doi.org/10.1093/cid/cis238
  • Plotkin SA. Complex correlates of protection after vaccination. Clin Infect Dis 2013; 56(10):1458-65; PMID:23386629; http://dx.doi.org/10.1093/cid/cit048
  • Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008; 47(3):401-9; PMID:18558875; http://dx.doi.org/10.1086/589862
  • Plotkin SA. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J 2001; 20(1):63-75; PMID:11176570
  • Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, Moxon ER, Stella M, Comanducci M, Bambini S, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. PNAS 2010; 20; 201013758; PMID:20962280
  • Plikaytis BD, Stella M, Boccadifuoco G, DeTora LM, Agnusdei M, Santini L, Brunelli B, Orlandi L, Simmini I, Giuliani M, et al. Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clin Vaccine Immunol 2012; 19(10):1609-17; PMID:22875603
  • Canada. Access to Information Act, R.S.C., 1985, c. A-1
  • AstraZeneca Canada Inc. v. Canada (Minister of Health), 2005 FC 189 at para. 65 (supplemental reasons 2005 FC 648, aff’d 2006 FCA 241).
  • Merck Frosst Canada Ltd. v. Canada (Health), [2012]1 S.C.R. 23.
  • Order PO-2557; Ontario (Ministry of the Environment), [2007]O.I.P.C. No. 61.
  • Canada Packers Inc. v. Canada (Minister of Agriculture), [1989]1 F.C. 47 (F.C.A.)
  • Jureidini JN, McHenry LB, Mansfield PR. Clinical trials and drug promotion: selective reporting of study 329. Int J Risk Saf Med 2008; 20(1):73-81
  • McGoey L, Jackson E. Seroxat and the suppression of clinical trial data: regulatory failure and the uses of legal ambiguity. J Med Ethics 2009; 35(2):107-12; PMID:19181884
  • European medicines agency, Publication and access to clinical-trial data, Policy/0070: Draft for public consultation, Jun. 24, 2013, available at: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2013/06/WC500144730.pdf ( last visited: Aug. 22, 2013)
  • Wasmuth EH, Miller WJ. Sensitive enzyme-linked immunosorbent assay for antibody to varicella-zoster virus using purified VZV glycoprotein antigen. J Med Virol 1990; 32(3):189-93; PMID:2177782
  • Provost PJ, Krah DL, Kuter BJ, Morton DH, Schofield TL, Wasmuth EH, White CJ, Miller WJ, Ellis RW. Antibody assays suitable for assessing immune responses to live varicella vaccine. Vaccine 1991; 9(2):111-6; PMID:1647574
  • Hammond O, Wang Y, Green T, Antonello J, Kuhn R, Motley C, Stump P, Rich B, Chirmule N, Marchese RD. The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection. J Med Virol 2006; 78(12):1679-87; PMID:17063506
  • Maple CPA, Gunn A, Sellwood J, Brown DW, Gray JJ. Comparison of fifteen commercial assays for detecting varicella zoster virus IgG with reference to a time resolved fluorescence immunoassay (TRFIA) and the performance of two commercial assays for screening sera from immunocompromised individuals. J Virol Methods 2009; 155(2):143-9; PMID:18996415
  • Sauerbrei A, Schäfler A, Hofmann J, Schacke M, Gruhn B, Wutzler P. Evaluation of three commercial varicella-zoster virus IgG enzyme-linked immunosorbent assays in comparison to the fluorescent-antibody-to-membrane-antigen test. Clin Vaccine Immunol 2012; 19(8):1261-8; PMID:22718131; http://dx.doi.org/10.1128/CVI.00183-12
  • International Committee of Medical Journal Editors, Uniform Requirements for manuscripts submitted to biomedical journals: ethical considerations in the conduct and reporting of research: Authorship and Contributorship, 2013, available at: http://www.icmje.org/ethical_1author.html (last visited: Nov. 14, 2013).
  • Canadian institutes of health research, CIHR Open Access Policy, Jan. 1, 2013, available at: http://www.cihr-irsc.gc.ca/e/32005.html (last visited: Nov. 14, 2013).